Addenda Capital Inc. Has $9.56 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Addenda Capital Inc. grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 7.8% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 48,662 shares of the medical research company’s stock after purchasing an additional 3,507 shares during the quarter. Addenda Capital Inc.’s holdings in IQVIA were worth $9,563,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of IQV. FMR LLC grew its holdings in IQVIA by 38.7% during the 3rd quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock worth $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of IQVIA during the 3rd quarter valued at about $147,683,000. JPMorgan Chase & Co. grew its stake in IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock worth $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB increased its holdings in IQVIA by 47.4% in the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its holdings in shares of IQVIA by 472.3% during the 2nd quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock worth $96,487,000 after buying an additional 376,595 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Stock Down 0.2 %

IQV stock opened at $197.25 on Tuesday. The stock has a market cap of $35.80 billion, a P/E ratio of 25.89, a P/E/G ratio of 2.01 and a beta of 1.48. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. The stock’s fifty day simple moving average is $200.09 and its two-hundred day simple moving average is $221.39. IQVIA Holdings Inc. has a 1-year low of $187.62 and a 1-year high of $261.73.

Wall Street Analyst Weigh In

IQV has been the subject of several research analyst reports. Morgan Stanley lowered their price objective on shares of IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Robert W. Baird reduced their target price on IQVIA from $213.00 to $212.00 and set a “neutral” rating for the company in a research note on Wednesday, December 11th. Evercore ISI dropped their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Truist Financial reduced their price objective on IQVIA from $265.00 to $261.00 and set a “buy” rating for the company in a research note on Thursday, December 12th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus price target of $255.82.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.